• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.

    5/14/26 6:20:30 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FHTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Foghorn Therapeutics Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    344174107

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    344174107


    1Names of Reporting Persons

    Deerfield Mgmt, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,139,523.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,139,523.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,139,523.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.64 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants, which, in each case, are held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


    SCHEDULE 13G

    CUSIP Number(s):
    344174107


    1Names of Reporting Persons

    Deerfield Management Company, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,139,523.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,139,523.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,139,523.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.64 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants, which, in each case, are held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


    SCHEDULE 13G

    CUSIP Number(s):
    344174107


    1Names of Reporting Persons

    Deerfield Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,139,523.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,139,523.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,139,523.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.64 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


    SCHEDULE 13G

    CUSIP Number(s):
    344174107


    1Names of Reporting Persons

    James E. Flynn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,139,523.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,139,523.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,139,523.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.64 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Comprised of (i) 4,394,367 shares of common stock and (ii) 745,156 shares of common stock issuable upon exercise of warrants, which, in each case, are held by Deerfield Partners, L.P. The provisions of the warrants beneficially owned by the reporting person restrict the exercise of such securities to the extent that after such exercise the holder, its affiliates and other persons whose beneficial ownership of common stock would be aggregated for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own in excess of 9.99% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the shares of common stock issuable upon exercise of such warrants to the extent that upon such exercise the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Foghorn Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    99 Coolidge Ave, Suite 500, Watertown, MA 02472
    Item 2. 
    (a)Name of person filing:

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.
    (b)Address or principal business office or, if none, residence:

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
    (c)Citizenship:

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn - United States citizen
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    344174107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Deerfield Mgmt, L.P. - 5,139,523 shares Deerfield Management Company, L.P. - 5,139,523 shares Deerfield Partners, L.P. - 5,139,523 shares James E. Flynn - 5,139,523 shares
    (b)Percent of class:

    Deerfield Mgmt, L.P. - 8.64% Deerfield Management Company, L.P. - 8.64% Deerfield Partners, L.P. - 8.64% James E. Flynn - 8.64%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    All Reporting Persons - 0

     (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 5,139,523 Deerfield Management Company, L.P. - 5,139,523 Deerfield Partners, L.P. - 5,139,523 James E. Flynn - 5,139,523

     (iii) Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 5,139,523 Deerfield Management Company, L.P. - 5,139,523 Deerfield Partners, L.P. - 5,139,523 James E. Flynn - 5,139,523

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit B
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Deerfield Mgmt, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/14/2026
     
    Deerfield Management Company, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/14/2026
     
    Deerfield Partners, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/14/2026
     
    James E. Flynn
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/14/2026
    Exhibit Information

    Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

    Get the next $FHTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX

    DatePrice TargetRatingAnalyst
    2/17/2026$12.00Buy
    Jefferies
    12/18/2025$11.00Buy
    BTIG Research
    11/7/2025$12.00Buy
    Guggenheim
    9/17/2025$10.00Buy
    B. Riley Securities
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    1/30/2025$10.00Buy
    B. Riley Securities
    9/3/2024$18.00Buy
    Jefferies
    8/19/2024$20.00Outperform
    Evercore ISI
    More analyst ratings

    $FHTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

    WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. H.C. Wainwright

    5/12/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

    - FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory  - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million; cash runway into the first half of 2028 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical

    5/7/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

    - Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer - Selective EP300 degrader outperforms clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy - Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a c

    4/21/26 4:05:00 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.

    SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    5/15/26 4:09:37 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.

    SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    5/14/26 6:20:30 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Foghorn Therapeutics Inc.

    10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)

    5/7/26 7:02:59 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gottschalk Adrian

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    4/13/26 4:01:20 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Maynard Ryan D

    4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    2/24/26 4:02:39 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Maynard Ryan D

    3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

    2/24/26 4:01:09 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Foghorn Therapeutics with a new price target

    Jefferies resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    2/17/26 7:49:23 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Foghorn Therapeutics with a new price target

    BTIG Research initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $11.00

    12/18/25 9:11:03 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Foghorn Therapeutics with a new price target

    Guggenheim initiated coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    11/7/25 8:30:10 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Foghorn Therapeutics Inc.

    SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    10/8/24 5:44:34 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Foghorn Therapeutics Inc.

    SC 13G - Foghorn Therapeutics Inc. (0001822462) (Subject)

    9/20/24 6:00:44 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

    SC 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)

    6/10/24 9:48:22 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    Leadership Updates

    Live Leadership Updates

    View All

    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies. "I am delighted to welcome Ryan to Foghorn as our new CFO as we continue to advance our first-in-class pipeline," said Adrian Gottschalk, Pres

    2/23/26 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ted Myles Joins Cellarity as Chief Executive Officer

    Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

    5/12/25 8:00:00 AM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $FHTX
    Financials

    Live finance-specific insights

    View All

    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

    First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 Robust preclinical monotherapy anti-tumor activity for both selective CBP and selective EP300 degrader programs Progress with FHD-909, selective CBP, and selective EP300 degrader programs further validates Foghorn's drug discovery engine Conference call and webcast today at 5 pm ET / 2 pm PT CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseas

    4/9/24 4:30:00 PM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

    Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, inclu

    3/26/24 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care